BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gorvin CM, Hannan FM, Howles SA, Babinsky VN, Piret SE, Rogers A, Freidin AJ, Stewart M, Paudyal A, Hough TA, Nesbit MA, Wells S, Vincent TL, Brown SD, Cox RD, Thakker RV. Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy. JCI Insight 2017;2:e91103. [PMID: 28194447 DOI: 10.1172/jci.insight.91103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Nemeth EF, Van Wagenen BC, Balandrin MF. Discovery and Development of Calcimimetic and Calcilytic Compounds. Elsevier; 2018. pp. 1-86. [DOI: 10.1016/bs.pmch.2017.12.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
2 Gorvin CM, Rogers A, Hastoy B, Tarasov AI, Frost M, Sposini S, Inoue A, Whyte MP, Rorsman P, Hanyaloglu AC, Breitwieser GE, Thakker RV. AP2σ Mutations Impair Calcium-Sensing Receptor Trafficking and Signaling, and Show an Endosomal Pathway to Spatially Direct G-Protein Selectivity. Cell Rep 2018;22:1054-66. [PMID: 29420171 DOI: 10.1016/j.celrep.2017.12.089] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
3 Leach K, Hannan FM, Josephs TM, Keller AN, Møller TC, Ward DT, Kallay E, Mason RS, Thakker RV, Riccardi D, Conigrave AD, Bräuner-Osborne H. International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function. Pharmacol Rev 2020;72:558-604. [PMID: 32467152 DOI: 10.1124/pr.119.018531] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
4 Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 2018;15:33-51. [PMID: 30443043 DOI: 10.1038/s41574-018-0115-0] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 42.0] [Reference Citation Analysis]
5 Howles SA, Hannan FM, Gorvin CM, Piret SE, Paudyal A, Stewart M, Hough TA, Nesbit MA, Wells S, Brown SD, Cox RD, Thakker RV. Cinacalcet corrects hypercalcemia in mice with an inactivating Gα11 mutation. JCI Insight 2017;2:96540. [PMID: 29046478 DOI: 10.1172/jci.insight.96540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tabacco G, Bilezikian JP. New Directions in Treatment of Hypoparathyroidism. Endocrinol Metab Clin North Am 2018;47:901-15. [PMID: 30390821 DOI: 10.1016/j.ecl.2018.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hannan FM, Olesen MK, Thakker RV. Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway. Br J Pharmacol 2018;175:4083-94. [PMID: 29127708 DOI: 10.1111/bph.14086] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
8 Diao J, DeBono A, Josephs TM, Bourke JE, Capuano B, Gregory KJ, Leach K. Therapeutic Opportunities of Targeting Allosteric Binding Sites on the Calcium-Sensing Receptor. ACS Pharmacol Transl Sci 2021;4:666-79. [PMID: 33860192 DOI: 10.1021/acsptsci.1c00046] [Reference Citation Analysis]
9 Patel J, Chuaiphichai S, Douglas G, Gorvin CM, Channon KM. Vascular wall regulator of G-protein signalling-1 (RGS-1) is required for angiotensin II-mediated blood pressure control. Vascul Pharmacol 2018;108:15-22. [PMID: 29654907 DOI: 10.1016/j.vph.2018.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Hannan FM, Gorvin CM, Babinsky VN, Olesen MK, Stewart M, Wells S, Cox RD, Nemeth EF, Thakker RV. Calcilytic NPSP795 Increases Plasma Calcium and PTH in an Autosomal Dominant Hypocalcemia Type 1 Mouse Model. JBMR Plus 2020;4:e10402. [PMID: 33103030 DOI: 10.1002/jbm4.10402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Dharmaraj P, Gorvin CM, Soni A, Nelhans ND, Olesen MK, Boon H, Cranston T, Thakker RV, Hannan FM. Neonatal Hypocalcemic Seizures in Offspring of a Mother With Familial Hypocalciuric Hypercalcemia Type 1 (FHH1). J Clin Endocrinol Metab 2020;105:dgaa111. [PMID: 32150253 DOI: 10.1210/clinem/dgaa111] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, Grout E, Tanikawa C, Kamatani Y, Terao C, Takahashi A, Kubo M, Matsuda K, Thakker RV, Turney BW, Furniss D. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat Commun 2019;10:5175. [PMID: 31729369 DOI: 10.1038/s41467-019-13145-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
13 Bove-fenderson E, Mannstadt M. Hypocalcemic disorders. Best Practice & Research Clinical Endocrinology & Metabolism 2018;32:639-56. [DOI: 10.1016/j.beem.2018.05.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
14 Gorvin CM, Babinsky VN, Malinauskas T, Nissen PH, Schou AJ, Hanyaloglu AC, Siebold C, Jones EY, Hannan FM, Thakker RV. A calcium-sensing receptor mutation causing hypocalcemia disrupts a transmembrane salt bridge to activate β-arrestin-biased signaling. Sci Signal 2018;11:eaan3714. [PMID: 29463778 DOI: 10.1126/scisignal.aan3714] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
15 Gorvin CM, Frost M, Malinauskas T, Cranston T, Boon H, Siebold C, Jones EY, Hannan FM, Thakker RV. Calcium-sensing receptor residues with loss- and gain-of-function mutations are located in regions of conformational change and cause signalling bias. Hum Mol Genet 2018;27:3720-33. [PMID: 30052933 DOI: 10.1093/hmg/ddy263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
16 Tuffour A, Kosiba AA, Zhang Y, Peprah FA, Gu J, Shi H. Role of the calcium-sensing receptor (CaSR) in cancer metastasis to bone: Identifying a potential therapeutic target. Biochim Biophys Acta Rev Cancer 2021;1875:188528. [PMID: 33640382 DOI: 10.1016/j.bbcan.2021.188528] [Reference Citation Analysis]
17 Frees S, Breuksch I, Haber T, Bauer HK, Chavez-Munoz C, Raven P, Moskalev I, D Costa N, Tan Z, Daugaard M, Thüroff JW, Haferkamp A, Prawitt D, So A, Brenner W. Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget 2018;9:15766-79. [PMID: 29644008 DOI: 10.18632/oncotarget.24607] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
18 Gorvin CM, Stokes VJ, Boon H, Cranston T, Glück AK, Bahl S, Homfray T, Aung T, Shine B, Lines KE, Hannan FM, Thakker RV. Activating Mutations of the G-protein Subunit α 11 Interdomain Interface Cause Autosomal Dominant Hypocalcemia Type 2. J Clin Endocrinol Metab 2020;105:dgz251. [PMID: 31820785 DOI: 10.1210/clinem/dgz251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol 2020;17:407-21. [PMID: 32533118 DOI: 10.1038/s41585-020-0332-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
20 Roberts MS, Gafni RI, Brillante B, Guthrie LC, Streit J, Gash D, Gelb J, Krusinska E, Brennan SC, Schepelmann M, Riccardi D, Bin Khayat ME, Ward DT, Nemeth EF, Rosskamp R, Collins MT. Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635). J Bone Miner Res 2019;34:1609-18. [PMID: 31063613 DOI: 10.1002/jbmr.3747] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
21 Gorvin CM, Hannan FM, Cranston T, Valta H, Makitie O, Schalin-Jantti C, Thakker RV. Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα11 Mutation. J Bone Miner Res 2018;33:32-41. [PMID: 28833550 DOI: 10.1002/jbmr.3241] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]